Cardinal Health expands home care with tuck-in acquisitions, but valuation remains stretched

What happened

Cardinal Health announced two tuck-in acquisitions to accelerate its at-Home Solutions growth strategy: the Diabetes Health business of AdaptHealth and urology-focused Strive Medical. These bolt-on deals reinforce the specialty/home-care pivot but are small relative to the $5.3B spent on MSO acquisitions in FY25. The master report already flagged rising acquisition-related amortization and leverage, and these additions increase integration complexity. While the news supports the growth narrative, it does not address key risks like CVS concentration, IRA margin pressure, or the widening GAAP vs. non-GAAP earnings gap. Overall, the risk/reward from today's elevated valuation remains skewed to the downside.

Implication

The tuck-in acquisitions align with Cardinal's strategy to expand higher-margin at-Home Solutions, a key part of the specialty pivot narrative. However, the master report's thesis remains unchanged: at ~22x FY26 non-GAAP EPS and with rising acquisition-related costs, the risk/reward is unfavorable. These deals are too small to alter the core risks of CVS concentration, IRA compression, and GAAP earnings quality. Investors should not overreact positively; hold positions small or trim into strength. The attractive entry point remains around $185, with a re-assessment window of 6-12 months.

Thesis delta

No material shift. The acquisitions are consistent with the specialty pivot and do not alter the investment thesis. The master report's POTENTIAL SELL rating and attractive entry at $185 remain intact. The incremental news supports the bullish narrative but does not reduce the asymmetric downside risk from high expectations and leverage.